Legal & General Group
SYRS

Legal & General Group’s Syros Pharmaceuticals, Inc. Common Stock SYRS Stock Holding History

Legal & General Group’s Portfolio SYRS Stock Details SYRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-459
Closed -$4K – 3499
2022
Q2 		$4K Sell
459
-74
-14% -$692 ﹤0.01% 3465
2022
Q1 		$6K Hold
533
– – ﹤0.01% 3497
2021
Q4 		$17K Hold
533
– – ﹤0.01% 3334
2021
Q3 		$24K Hold
533
– – ﹤0.01% 3221
2021
Q2 		$29K Buy
533
+18
+3% +$1.06K ﹤0.01% 3154
2021
Q1 		$39K Sell
515
-1,226
-70% -$127K ﹤0.01% 2904
2020
Q4 		$189K Buy
1,741
+1,227
+239% +$112K ﹤0.01% 2439
2020
Q3 		$45K Sell
514
-170
-25% -$19.3K ﹤0.01% 2732
2020
Q2 		$73K Buy
684
+113
+20% +$10.1K ﹤0.01% 2614
2020
Q1 		$31K Sell
571
-145
-20% -$9.84K ﹤0.01% 2752
2019
Q4 		$49K Buy
716
+137
+24% +$8.31K ﹤0.01% 2820
2019
Q3 		$60K Hold
579
– – ﹤0.01% 2678
2019
Q2 		$46K Buy
579
+137
+31% +$9.54K ﹤0.01% 2811
2019
Q1 		$40K Buy
442
+77
+21% +$5.36K ﹤0.01% 2794
2018
Q4 		$20K Hold
365
– – ﹤0.01% 3088
2018
Q3 		$43K Hold
365
– – ﹤0.01% 2855
2018
Q2 		$37K Buy
365
+108
+42% +$13.4K ﹤0.01% 2908
2018
Q1 		$33K Sell
257
-103
-29% -$11.3K ﹤0.01% 2951
2017
Q4 		$35K Buy
360
+49
+16% +$6.58K ﹤0.01% 2987
2017
Q3 		$46K Buy
311
+92
+42% +$17.3K ﹤0.01% 2932
2017
Q2 		$36K Buy
219
+161
+278% +$25.3K ﹤0.01% 2993
2017
Q1 		$9K Hold
58
– – ﹤0.01% 3206
2016
Q4 		$7K Buy
+58
New +$8.13K ﹤0.01% 3267

Other funds holding SYRS

AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
ABG
Ally Bridge Group New York $124M AUM 249.88% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CH
CVI Holdings Wilmington, Delaware $116M AUM 5.68% 1-Year Est. Return
DCM
DAFNA Capital Management Los Angeles, California $440M AUM 109.12% 1-Year Est. Return

Legal & General Group's SYRS Position: Q3 2022 in Review

Legal & General Group sold out of Syros Pharmaceuticals, Inc. Common Stock (SYRS) in Q3 2022, closing a stake of 459 shares — an estimated $4K sold.

Legal & General Group first reported a position in SYRS in Q4 2016 and held it in 23 quarters. The position peaked at $189K in Q4 2020. 53 funds tracked by Wall St. Rank hold SYRS as of Q3 2022.

  • Legal & General Group reported no remaining Syros Pharmaceuticals, Inc. Common Stock position as of Q3 2022 after selling out during the quarter.
  • Legal & General Group sold 459 Syros Pharmaceuticals, Inc. Common Stock shares in Q3 2022, an estimated $4K.
  • Legal & General Group first reported a position in Syros Pharmaceuticals, Inc. Common Stock in Q4 2016 and held it in 23 quarters.
  • Legal & General Group's Syros Pharmaceuticals, Inc. Common Stock position peaked at $189K in Q4 2020.
  • 53 funds tracked by Wall St. Rank held Syros Pharmaceuticals, Inc. Common Stock as of Q3 2022.

Based on Legal & General Group's 13F filing for Q3 2022, filed 14 Nov 2022.